Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials
1. Interim data for LX2006 shows significant cardiac improvements in Friedreich ataxia patients. 2. 5 of 6 participants achieved normal LVMI, indicating strong treatment efficacy. 3. 27% mean LVMI improvement reflects dose-dependent efficacy across treatment cohorts. 4. All participants noted increased frataxin protein expression in cardiac biopsies. 5. Lexeo plans a registrational study by early 2026, aiming for a 2027 readout.